Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants Greg Fraser - Truist David Amsellem - Piper Sandler Serge Belanger - Needham & Company Tim Lugo - William Blair Operator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2022 Earnings Call. [Operator Instructions] Please note that this conference is be ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or ...

May 10, 2022 | Nasdaq: COLL Q1FY22 Earnings Report | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications Joe Ciaffoni - President and CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants David Amsellem - Piper Sandler Lachlan Hanbury-Brown - William Blair Serge Belanger - Needham & Co. Greg Fraser - Truist Securities Brandon Folkes - Cantor Fitzgerald Operator Greetings, and welcome to Collegium Pharmaceutical, Inc. F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations & Corporate Communications Joe Ciaffoni - President, CEO & Director Colleen Tupper - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler & Co. Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Lachlan Hanbury-Brown - William Blair Greg Fraser - Truist Securities Disclai ...

| --- | --- | --- | |-------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Q4 and FYE 2021 Earnings Report | | | | February 24, 2022 \| Nasdaq: COLL | | | | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Julie Fallon - Senior Vice President, Investor Relations, MacDougall Advisors Joe Ciaffoni - President, CEO & Director Colleen Tupper - EVP & CFO Scott Dreyer - EVP & Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler & Co. David Steinberg - Jefferies Serge Belanger - Needham & Company Oren Livnat - H.C. Wainwright Greg Fraser - Truist Securities Op ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (Sta ...